HEATON LARRY C II

CEO HEATON LARRY C II bought 500,000 shares (500.0K shares) for $29,702.29 across 4 transactions, doubling holdings to 1,000,000 shares (1.00M shares).

CEO HEATON LARRY C II executed 4 separate purchases totaling 500,000 shares (500.0K shares) for $29,702.29 at a blended average price of $0.06 on 2025-03-17, doubling his holdings from 500,000 shares (500.0K shares) to 1,000,000 shares (1.00M shares). This substantial open-market acquisition occurs while ZOM trades -44.4% from its 52-week high ($0.18) and -18.6% over the past 30 days. The company remains unprofitable with a net income of $-6,697,000.00 ($-6.7M) against revenue of $6,997,000.00 ($7.0M) in the latest quarter. A cluster of 7 other insiders also bought within the past 14 days, suggesting coordinated conviction at current valuations. His prior 5 buys at ZOM show mixed 90-day results (2 of 5 well-timed), indicating his stock-picking timing at this ticker lacks consistent precision.

CEO Heaton bought 100.0K ZOM shares at $0.12; +25.0% increase to 500.0K holdings; stock -36.4% from 52-week high, cluster buy pattern detected.

CEO Larry C Heaton II purchased 100,000 shares at $0.12, bringing total holdings to 500,000 shares (+25.0% increase). The transaction occurs when ZOM trades at $0.14, which is -36.4% from its 52-week high of $0.22, suggesting accumulation at depressed levels. The purchase coincides with a broader pattern: 3 other insiders also bought ZOM within the past 14 days, indicating coordinated insider interest. However, his prior trades at ZOM show mixed results—2 of 4 measurable prior buys (50%) achieved positive 90-day returns. The company remains unprofitable (net income $-6.7M last quarter) despite +33.0% annual revenue growth, creating uncertainty about operational trajectory. This filing warrants monitoring to assess whether the insider cluster and recent revenue growth signal stabilization or reflect investment in an unproven turnaround.

ZOM CEO buys 100.0K shares at $0.12; holdings increase to 400.0K (+33.3%). Stock down -40.9% from 52-week high.

CEO Larry C Heaton II purchased 100,000 shares at $0.12 on 2024-09-05, expanding his stake from 300,000 to 400,000 shares. His prior ZOM trades show mixed outcomes: a May 2024 buy returned +7.1% in 30 days and +4.2% in 90 days, but two earlier purchases (November 2023 and May 2023) underperformed over 90 days, with one declining -16.3%. The current share price of $0.13 sits -40.9% below the 52-week high, and the stock has declined -13.3% in the past 30 days and -12.5% over 90 days. Zomedica remains unprofitable with net income of -$23.9M against quarterly revenue of $6.1M, though annual revenue growth reached +33.0%. The purchase follows a period of sharp price erosion and occurs at a price matching the 52-week low, but the insider's historical timing at this ticker—only 1 of 3 prior buys were well-timed at the 90-day mark—suggests limited predictive power from his prior accumulation decisions.